The Global Structural Heart Devices Market was valued at USD 7.56 billion in 2024 and is anticipated to reach USD 20.72 billion by 2035, expanding at a CAGR of 9.60% during the forecast period 2025-2035. Continued increase in the global burden of cardiovascular diseases is setting unprecedented demand for advanced interventional technologies in structural heart therapy. Several factors include the effect of ageing populations and the increasing incidence of valvular disorders and patient preference for minimally invasive interventions, which stimulate medical device manufacturers.
Over the years, structural heart devices have defined the treatment paradigm in healthcare systems, which replaces open-heart surgery with designs involving innovative catheter-based techniques for faster recovery, shorter hospital stays, and better outcomes for patients. Besides growing awareness, advances in technology also include imaging, robotics, and device engineering, which broaden adoption. All stakeholders, from cardiologists to regulatory bodies, are collaborating to develop strong clinical evidence for broad reimbursement and
adoption.
Meanwhile, increased healthcare expenditure, especially in developing countries, has opened enormous avenues for growth for manufacturers willing to penetrate untapped markets. The new feature among structural heart device companies is that clinical effectiveness is not enough, as it also has to be supported by evidence of cost efficiency, thereby integrating innovative technologies within the constraints of healthcare systems with limited resources. Manufacturers reshuffled their product portfolios to introduce much more durable and next-generation devices that can handle complex patient anatomies in high-risk surgical settings. By converging digital technologies such as AI-guided imaging and 3D printing into product development, market leaders are seeking to create a competitive advantage in precision medicine. This is not just a step towards evolution but a transformational one in defining patient care pathways and setting a new standard in interventional cardiology.
Rising valvular heart disease drives global demand for advanced structural interventions and minimally invasive cardiac devices.
Increased occurrences of aortic stenosis, mitral regurgitation, and atrial fibrillation have resulted in a constant need for structures to develop heart devices. With population ageing and increased life expectancy, there is an increase in hospital patients deemed ineligible for conventional surgeries. More invasive techniques, such as TAVR and mitral repair, emerged as life-saving alternatives because the available recovery periods were announced as shorter, resulting in an improved lifestyle. Thus, penetration into both mature and emerging markets gained acceleration, buoyed by increased physician expertise and better clinical trial evidence supporting device safety and efficacy.
High costs and restrictive reimbursement policies challenge global adoption of advanced structural heart disease interventions.
Increased technical achievement may not trigger profitability because reimbursement may not align properly within the same time frame. Some payers across geographies tend to be more conservative in granting widespread reimbursement approval at the very early phase of aftermarket entrance for many emerging therapies, particularly when long-term outcome data are not well established. Affordability issues continue in low- and middle-income countries; with the huge amounts required, it becomes difficult for healthcare systems to consider most of them for wide adoption. Thus, while demonstrating cost-effectiveness and real-world impact, manufacturers must also engage with regulators and healthcare providers to widen reimbursement frameworks.
Innovation in imaging, AI, and materials drives personalised, durable devices for precision structural heart interventions globally.
Advanced imaging, AI-based procedural planning, and next-generation materials are converging to create new frontiers in device design and durability. A hybrid approach-research into surgical versus catheter-based interventions, producing gains in efficacy for some of the most complex anatomies. 3D printing, novel polymer coatings, and biocompatible materials are developing devices that would be superior in performance and have lower complication rates. This wave of innovation extends into personalised medicine, whereby customised devices are developed to match a patient's anatomy because personalisation increases uptake and procedure success rates.
Supply chain, regulatory, and training gaps challenge structural heart device adoption despite technological innovation globally.
At present, the upshot of such innovative technology-coupled with the very stimulating world of structural heart devices, is along volatile supply chains for critical components coupled with stringent regulatory hurdles that prolong approval timelines. As if this were not enough, the entire learning curve associated with advanced interventional procedures creates what is known as the training gap, particularly in developing markets where there are fewer skilled interventional cardiologists. These dynamic limits the pace of adoption despite good patient outcomes. Therefore, companies are investing heavily in physician training programs and digital learning hubs to address these constraints while pursuing regulatory harmonisation across the regions.
By Type: Surgical Aortic Valve Replacement, Transcatheter Aortic Valve Replacement, Mitral Repair, Left Atrial Appendage Closure
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, CryoLife Inc., Lepu Medical Technology, MicroPort Scientific Corporation, JenaValve Technology Inc., and Meril Life Sciences Pvt. Ltd.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 295
TAVR leads structural heart device market, fueled by ageing populations and preference for minimally invasive procedures.
Transcatheter aortic valve replacement (TAVR) swiftly emerged as a leading force in the structural heart devices market. Initially, offered to
patients at prohibitive surgical risk, TAVR is now being increasingly offered for intermediate and low-risk patients following successful completion of clinical trials such as PARTNER 3 and Evolut Low Risk. Shorter hospital stays, fewer complications, and a quicker return to normal activities have made TAVR the treatment of choice in various health systems. To further enhance the adoption of TAVR, iterations of the device with improved repositionability, greater haemodynamic performance, and durability are also being developed. TAVR's fast-paced growth and maximal influence are expected under guideline updates in Europe and the U.S.
Mitral repair segment grows rapidly, addressing unmet mitral regurgitation needs and expanding minimally invasive treatment options.
The mitral repair segment has been gaining momentum as physicians are beginning to embrace the function of transcatheter repair devices to mitigate mitral regurgitation, especially in patients who are poor surgical candidates. Devices such as MitraClip have entered the realm of Standard of Care across numerous areas and provide symptomatic relief for heart failure patients, decreasing hospitalisations. The much higher incidence of mitral valve disease compared to aortic stenosis means there is a large growth opportunity for this segment. More research and development on new devices addressing primary and secondary mitral regurgitation are likely to further change treatment paradigms, with the aid of favourable reimbursement decisions and ongoing clinical evidence.
Left atrial appendage closure devices gain prominence, preventing strokes and expanding options for atrial fibrillation patients globally.
With atrial fibrillation emerging as a global health burden, stroke prevention has become a clinical and economic priority. Left atrial appendage closure (LAAC) devices have positioned themselves as an alternative to lifelong anticoagulation therapy, especially for patients at high bleeding risk. Established clinical evidence regarding their use from trials such as PROTECT AF and PRAGUE-17 reinforces this evidence of improved stroke risk reduction and long-term outcomes. Continued growth will be stimulated by increasing physician familiarity with the device, improved implantation techniques, and wider reimbursement coverage. Given the growing prevalence of atrial fibrillation in elderly societies, the LAAC device market will see vigorous growth in developed and developing regions.
Surgical aortic valve replacement maintains relevance, complementing TAVR and serving younger patients needing durable solutions.
While transcatheter methods are gaining prevalence, surgical aortic valve replacement (SAVR) will maintain its pivotal role, particularly for the younger patients needing durable prosthetic valves. Surgical approaches still reign in these patients with complex valve pathologies or when an intervention on the heart is required concurrently. Innovations in surgical bioprosthetic valves with augmented durability and biocompatibility serve to keep this arena vivacious and in high demand. The interaction between SAVR and TAVR signifies how both surgical and transcatheter modes complement each other, thereby ensuring a stable contribution from the surgical field, notwithstanding the turbulence that may exist in the larger area.
North America leads structural heart devices market with advanced infrastructure, high procedure adoption, and strong regulatory support.
North America remains the largest regional market for structural heart devices, driven by a well-established healthcare infrastructure and significant patient volumes for valvular and atrial fibrillation procedures. The United States, in particular, has seen accelerated adoption of TAVR and mitral repair therapies, supported by favourable reimbursement frameworks and a concentration of leading manufacturers such as Edwards, Abbott, and Medtronic. The presence of world-class clinical trial centres and strong regulatory clarity from the FDA further reinforces the region-s leadership. With stroke prevention gaining clinical emphasis, left atrial appendage closure devices are also witnessing rising procedural volumes across top-tier hospitals.
Europe leads structural heart device adoption through proactive approvals, advanced training, and expanding clinical procedure indications.
Europe continues to act as a pioneering hub for structural heart innovation, driven by proactive regulatory approvals under CE Mark and adoption in early-stage risk groups. Countries such as Germany, France, and the UK are at the forefront of procedure volumes, with robust training programmes accelerating physician expertise. The European market is also benefiting from substantial government-backed investments into cardiovascular research, facilitating faster integration of advanced technologies into clinical practice. Mitral repair and tricuspid therapies, in particular, are gaining stronger traction across Europe, setting the stage for future growth as reimbursement frameworks expand.
Asia-Pacific leads structural heart device growth with ageing populations, healthcare investments, and expanding local manufacturing capabilities.
Asia-Pacific is expected to witness the highest CAGR in the forecast period, underpinned by an expanding elderly population, increasing prevalence of cardiovascular disease, and rapidly improving healthcare infrastructure. China, India, and Japan are at the core of this growth, supported by substantial government investments in healthcare and growing private hospital networks. Local manufacturers such as Lepu Medical and MicroPort are bolstering regional supply, enhancing accessibility at lower price points. Training collaborations and strategic partnerships with Western device companies are enabling knowledge transfer, further accelerating adoption across this diverse region.
LAMEA structural heart device market grows with rising awareness, healthcare investments, and expanding cardiovascular infrastructure.
The LAMEA region, although comparatively nascent in adoption, is showing promising growth prospects fuelled by rising awareness of minimally invasive therapies and increasing healthcare expenditure. Countries like Brazil, the UAE, and Saudi Arabia are emerging as focal markets due to substantial investments in cardiovascular care infrastructure. Medical tourism is also propelling procedural adoption, particularly in the Middle East. While affordability challenges persist in parts of Africa and Latin America, strategic partnerships and international aid programmes are expected to gradually increase accessibility. Over the forecast period, this region is set to transform into a lucrative growth corridor for structural heart device manufacturers.
Q. What is the expected growth trajectory of the structural heart devices market from 2024 to 2035?
The global structural heart devices market is projected to grow from USD 7.56 billion in 2024 to USD 20.72 billion by 2035, registering a CAGR of 9.6%. This growth is driven by expanding adoption of minimally invasive valve replacement and repair procedures, alongside rising demand for stroke prevention solutions.
Q. Which key factors are fuelling the growth of the structural heart devices market?
Several key factors are propelling market growth:
Q. What are the primary challenges hindering the growth of the structural heart devices market?
Major challenges include:
Q. Which regions currently lead the structural heart devices market in terms of market share?
North America currently leads the structural heart devices market due to robust industrial infrastructure, strong reimbursement systems, and rapid clinical adoption. Europe closely follows with a leadership position in early adoption and clinical innovation.
Q. What emerging opportunities are anticipated in the structural heart devices market?
The market is ripe with new opportunities, including: